UBS Raises Human Genome Price Target to $25 Based on Acquisition Potential

Human Genome's price target was raised at UBS to $25 from $18 taking into account its acquisition potential. UBS believes that Glaxosmithkline (GSK) is the obvious acquirer didn’t dare to predict it. The firm rates shares a Buy.